Balanced news tone
News Sentiment
STRO sentiment intelligence
Sutro Biopharma news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
57
Balanced news tone
66 relevant articles
News tone and price action are not far from neutral.
77/100 classification confidence.
directly relevant articles
high-authority source matches
-2.3% over one week, +3.2% over four weeks, trend active, and near fair-value range.
Sutro Biopharma, Inc. Common Stock (STRO) Stock Price Today: $26.03
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Market update
77/100 classification
One-week reaction
-2.3%
Price reacting lower
Trend fit
Trend active
3.2% over four weeks
Fair value
13.0%
Near fair-value range
Sentiment Mix
Positive, neutral, negative
Positive
27
Neutral
32
Negative
7
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Gotrade
Direct company coverage
Sutro Biopharma, Inc. Common Stock (STRO) Stock Price Today: $26.03
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jul 2026 03:27
- Source
- Gotrade
Market source
Industry context
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 12:30
- Source
- Market source
Quartr
Direct company coverage
Sutro Biopharma (STRO) TD Cowen 46th Annual Health Care Conference Summary
Sutro Biopharma presented at the TD Cowen 46th Annual Health Care Conference, highlighting its strategic transformation, leadership overhaul, and extended financial runway into Q2 2028. The company emphasized its proprietary ADC platform, which enables optimization of all compone
- Tone
- Positive 74/100
- Event
- Market update
- Published
- 09 Jul 2026 21:39
- Source
- Quartr
Quartr
Direct company coverage
Sutro Biopharma (STRO) 2024 Wells Fargo Healthcare Conference Summary
Sutro Biopharma presented at the 2024 Wells Fargo Healthcare Conference, highlighting its focus on late-stage oncology clinical development and its proprietary antibody-drug conjugate (ADC) platform. The company's lead program, Luvelta, is in pivotal trials for ovarian cancer, pe
- Tone
- Positive 72/100
- Event
- Market update
- Published
- 09 Jul 2026 09:39
- Source
- Quartr
TradingView
Direct company coverage
Price to book forward of Sutro Biopharma, Inc. – NASDAQ:STRO
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Jul 2026 03:45
- Source
- TradingView
MSN
Direct company coverage
Sutro Biopharma (STRO) price target increased by 13.85% to 37.74
This article reports that the price target for Sutro Biopharma (STRO) has been increased by 13.85% to $37.74. No further details are provided in the given content beyond this financial adjustment.
- Tone
- Positive 76/100
- Event
- Analyst action
- Published
- 05 Jul 2026 08:41
- Source
- MSN
www.marketscreener.com
Direct company coverage
Sutro Biopharma, Inc.(NasdaqGM: STRO) added to Russell 2000 Dynamic Index
Sutro Biopharma, Inc. (NasdaqGM: STRO) has been added to the Russell 2000 Dynamic Index, as announced on June 28, 2026. This inclusion is part of a series of additions to various Russell indices for the biotechnology company, which specializes in developing oncology therapeutics
- Tone
- Positive 67/100
- Event
- Market update
- Published
- 30 Jun 2026 23:11
- Source
- www.marketscreener.com
TradingView
Direct company coverage
Sutro Biopharma, Inc. Actuals & Estimates (LSX:A41VMF)
This article provides an overview of Sutro Biopharma, Inc. (A41VMF) stock performance, financial actuals, and analyst estimates. It highlights a recent 15% increase in stock price, with analysts forecasting a wide range for future price targets. Key financial data like market cap
- Tone
- Positive 64/100
- Event
- Analyst action
- Published
- 27 Jun 2026 01:10
- Source
- TradingView
TradingView
Direct company coverage
Sutro Biopharma, Inc. Actuals & Estimates (NASDAQ:STRO)
This article provides an overview of Sutro Biopharma, Inc. (NASDAQ: STRO) including its current stock price, market capitalization, historical performance, and analyst forecasts. It also delves into the company's financial actuals and estimates, covering earnings per share, reven
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 26 Jun 2026 20:10
- Source
- TradingView
TradingView
Direct company coverage
STRO Forecast — Price Target — Prediction for 2027
This article provides a forecast for Sutro Biopharma, Inc. (STRO) stock, including price targets, analyst ratings, and financial performance data. It details the current stock price, historical highs and lows, market capitalization, and upcoming earnings reports. The article also
- Tone
- Positive 61/100
- Event
- Analyst action
- Published
- 26 Jun 2026 10:09
- Source
- TradingView
TradingView
Direct company coverage
Sutro Biopharma, Inc. Actuals & Estimates (GETTEX:S090)
This article provides an overview of Sutro Biopharma, Inc. (S090) stock performance on GETTEX, including current price, historical highs and lows, and analyst forecasts. It details financial actuals and estimates, such as earnings per share and revenue, and provides information o
- Tone
- Positive 64/100
- Event
- Earnings
- Published
- 26 Jun 2026 03:09
- Source
- TradingView
TradingKey
Direct company coverage
Sutro Biopharma Inc (STRO) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Sutro Biopharma Inc (STRO), examining its price momentum, support and resistance levels, and various technical indicators and moving averages. According to the analysis, STRO's momentum score is 9.29, and it is suitable for range-boun
- Tone
- Positive 60/100
- Event
- Market update
- Published
- 24 Jun 2026 03:39
- Source
- TradingKey
Moomoo
Direct company coverage
Barclays Maintains Sutro Biopharma(STRO.US) With Buy Rating, Maintains Target Price $56
Barclays has reiterated its Buy rating on Sutro Biopharma (STRO.US) and maintained its target price of $56. This indicates continued confidence from the financial institution in the company's stock performance.
- Tone
- Positive 90/100
- Event
- Analyst action
- Published
- 23 Jun 2026 15:14
- Source
- Moomoo
TradingKey
Direct company coverage
Sutro Biopharma Inc (STRO) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for Sutro Biopharma Inc (STRO), highlighting its current risk score of 1.04, which ranks it 334 out of 389 in the Biotechnology & Medical Research industry. Key metrics like a beta of 1.57, volatility figures, and Sharpe Ratios are presente
- Tone
- Negative 39/100
- Event
- Market update
- Published
- 23 Jun 2026 06:41
- Source
- TradingKey
TradingKey
Direct company coverage
Sutro Biopharma Inc (STRO) Institutional Confidence
The article analyzes the institutional confidence in Sutro Biopharma Inc (STRO), noting a current shareholding score of 3.00, which ranks 193 out of 389 in its industry. The institutional shareholding proportion decreased by 31.45% quarter-over-quarter to 45.76%. Steven Cohen is
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 Jun 2026 01:40
- Source
- TradingKey
TradingKey
Direct company coverage
Sutro Biopharma Inc (STRO) Earnings Forecast: Future EPS & Revenue Growth Estimates
Sutro Biopharma Inc (STRO) has an earnings forecast score of 8.15, ranking 158th in the Biotechnology & Medical Research industry. Analysts have set an average price target of $30.00, with a bullish "Buy" rating from most of the 14 analysts covering the stock. The company's recen
- Tone
- Positive 70/100
- Event
- Earnings
- Published
- 18 Jun 2026 14:09
- Source
- TradingKey
TradingKey
Direct company coverage
Sutro Biopharma Inc (STRO) Valuation: PE, PB & Fair Value Analysis
Sutro Biopharma Inc (STRO) has a current valuation score of 8.56, placing it 116th out of 388 companies in the Biotechnology & Medical Research industry. The company's P/E ratio is -1.74, which is significantly below its recent high and above its recent low. However, relevant dat
- Tone
- Positive 59/100
- Event
- Market update
- Published
- 18 Jun 2026 11:09
- Source
- TradingKey
TradingKey
Direct company coverage
Sutro Biopharma Inc (STRO) Financial Health: Profitability & Balance Sheet Analysis
Sutro Biopharma Inc (STRO) has a financial score of 8.14, ranking 61st out of 388 in the Biotechnology & Medical Research industry, indicating a weak financial status despite high operating efficiency. The company's latest quarterly revenue decreased by 16.53% year-over-year to $
- Tone
- Negative 38/100
- Event
- Earnings
- Published
- 18 Jun 2026 10:40
- Source
- TradingKey
The Business Journals
Direct company coverage
This drug 'gave our daughter another chance' — now a nonprofit's deal hopes to secure its use for years to come
Sutro Biopharma has ceased its development of a leukemia drug, but a nonprofit organization, Blood Cancer United, has taken control of the remaining supply. The drug has been crucial for patients like Aspen Peck, who was treated for a rare and aggressive form of childhood blood c
- Tone
- Positive 63/100
- Event
- Deals and strategy
- Published
- 15 Jun 2026 21:40
- Source
- The Business Journals
Simply Wall Street
Direct company coverage
Sutro Biopharma (Nasdaq:STRO) - Stock Analysis
Sutro Biopharma (STRO) is an oncology company with a market cap of US$500.4 million, currently 41.7% undervalued by analysts. The company faces financial risks, including negative shareholder equity, dilution, and a forecast decline in earnings, but analysts have recently increas
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 15 Jun 2026 00:10
- Source
- Simply Wall Street
Moomoo
Direct company coverage
Truist Financial Initiates Sutro Biopharma(STRO.US) With Buy Rating, Announces Target Price $50
Truist Financial has initiated coverage on Sutro Biopharma (STRO.US) with a Buy rating. The firm has set a price target of $50 for the company's stock. This new rating and target price indicate a positive outlook from Truist Financial on Sutro Biopharma's future performance.
- Tone
- Positive 80/100
- Event
- Analyst action
- Published
- 11 Jun 2026 23:08
- Source
- Moomoo
Moomoo
Direct company coverage
Sutro Biopharma Price Target Announced at $50.00/Share by Truist Securities
Truist Securities has set a price target of $50.00 per share for Sutro Biopharma (NASDAQ: STRO). This new target suggests a potential upside for shareholders compared to the stock's current trading price. The adjustment reflects Truist Securities' latest assessment of Sutro Bioph
- Tone
- Positive 77/100
- Event
- Analyst action
- Published
- 11 Jun 2026 13:09
- Source
- Moomoo
Stock Titan
Direct company coverage
Sutro Biopharma (STRO) director awarded 10,000 stock options at $26.09 strike
Sutro Biopharma director James P. Panek was granted 10,000 stock options with an exercise price of $26.09 per share, expiring on June 5, 2036. The options will vest monthly, starting July 5, 2026, and will be fully vested by June 5, 2027, or the 2027 annual stockholders meeting,
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jun 2026 20:39
- Source
- Stock Titan
Stock Titan
Direct company coverage
Sutro Biopharma (STRO) director receives 10,000 stock options at $26.09
SUTRO BIOPHARMA, INC. director Jon Marc Wigginton was granted 10,000 stock options at an exercise price of $26.09 per share on June 5, 2026. These options represent equity-based compensation and will vest monthly at a rate of 8.33% starting July 5, 2026, contingent on his continu
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jun 2026 20:25
- Source
- Stock Titan
Stock Titan
Direct company coverage
Sutro Biopharma (STRO) director receives 10,000 options vesting into 2027
Sutro Biopharma director Joseph M. Lobacki was granted 10,000 stock options with an exercise price of $26.09 per share, expiring on June 5, 2036. The options will vest monthly starting July 5, 2026, and become fully vested by the company's 2027 annual shareholders meeting or June
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jun 2026 20:20
- Source
- Stock Titan
Stock Titan
Direct company coverage
Sutro Biopharma (STRO) director receives 10,000-share stock option grant
Sutro Biopharma director Jagpal Sukhi was granted 10,000 stock options with an exercise price of $26.09 per share, expiring on June 5, 2036. This compensation-related award vests monthly, with the first tranche starting July 5, 2026, and will be fully vested by the earlier of the
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jun 2026 20:18
- Source
- Stock Titan
Stock Titan
Direct company coverage
[Form 4] SUTRO BIOPHARMA, INC. Insider Trading Activity
Sutro Biopharma director Heidi Hunter was granted 10,000 stock options at an exercise price of $26.09 per share, expiring on June 5, 2036. The options vest monthly over approximately one year, commencing July 5, 2026, and are fully vested by the earlier of the 2027 annual stockho
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jun 2026 20:16
- Source
- Stock Titan
Quartr
Direct company coverage
Sutro Biopharma (STRO) Proxy filing Summary
Sutro Biopharma (STRO) released a proxy filing summary for its upcoming annual meeting on June 5, 2026, which will be held virtually. Key proposals include the election of three Class II directors, the ratification of Ernst & Young LLP as auditor for 2026, and an advisory vote on
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jun 2026 02:40
- Source
- Quartr
Stock Titan
Direct company coverage
Sutro Biopharma (NASDAQ: STRO) reports 2026 annual meeting results
Sutro Biopharma, Inc. (NASDAQ: STRO) announced the results of its 2026 Annual Meeting of Stockholders held on June 5, 2026. Shareholders elected three Class II directors—Jane Chung, Connie Matsui, and James Panek—and approved two additional proposals, including the ratification o
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 08 Jun 2026 20:00
- Source
- Stock Titan
Finviz
Direct company coverage
STRO - Sutro Biopharma Inc Stock Price and Quote
This article provides comprehensive financial data, stock performance metrics, and analyst ratings for Sutro Biopharma Inc. (STRO). It details insider transactions, company leadership information, and a timeline of news events related to the company's clinical trials, financial r
- Tone
- Positive 62/100
- Event
- Analyst action
- Published
- 04 Jun 2026 07:40
- Source
- Finviz